Compare INUV & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INUV | BOLD |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.3M | 25.7M |
| IPO Year | 1996 | 2024 |
| Metric | INUV | BOLD |
|---|---|---|
| Price | $1.86 | $1.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $11.00 | $4.00 |
| AVG Volume (30 Days) | ★ 217.9K | 96.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $86,209,305.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.88 | N/A |
| 52 Week Low | $0.34 | $0.96 |
| 52 Week High | $6.27 | $1.78 |
| Indicator | INUV | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 79.51 |
| Support Level | $1.83 | $1.12 |
| Resistance Level | $1.99 | N/A |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 13.73 | 80.33 |
Inuvo Inc is an advertising technology and services company that has developed and commercialized large language generative artificial intelligence (AI) for modeling media audiences. Its products and services include ValidClick and IntentKey. The company's platforms identify and message online audiences for any product or service across devices, channels, and formats, including video, mobile, connected TV, display, social, and native. It has clients from various industries that include retail, automotive, insurance, health care, technology, telecommunications and finance. Inuvo's revenue is derived from the placement of digital advertising throughout devices, websites, applications and browsers across social, search and programmatic advertising channels.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.